Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir Intensification in HIV with Poor Immune Recovery
NCT01245101Phase 4Terminated
- Sponsor
- University of Miami
- Start
- Nov 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of raltegravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Miami. Primary endpoint: Episomal HIV cDNA Formation at 16 weeks. Started Nov 2010; status: terminated.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01245101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01245101.